remifentanil + doxophylline + naloxone + sugammadex sodium

remifentanil + doxophylline + naloxone + sugammadex sodium is a pharmacological combination regimen investigated for its efficacy in accelerating and improving the quality of recovery from general anesthesia. This protocol, primarily studied by Taizhou Hospital of Zhejiang Province, utilizes remifentanil as the primary anesthetic and analgesic agent. To facilitate emergence, naloxone is administered to antagonize opioid-induced respiratory depression and sedation, doxophylline is used as a methylxanthine bronchodilator to stimulate respiratory drive and improve pulmonary function, and sugammadex sodium is employed as a selective relaxant binding agent to rapidly reverse neuromuscular blockade induced by aminosteroid agents like rocuronium. The combination aims to reduce the time to extubation and minimize post-operative complications in patients undergoing surgery.